One step closer to personalized medicine

On September 21-23, 2015, the p-medicine consortium composed of 19 partner organisations from all over Europe and Japan came together for their final project meeting in Homburg/Saar, Germany. During the meeting, the project's final achievements were presented to representatives of the European Commission, the local government as well as interested companies, research institutions and patient/parents groups.

The project’s research resulted in a series of computer-based tools, which will help cancer patients to better understand the nature of their disease and support clinicians in finding the right treatment for the individual patient by analyzing ‘big data’ from individual patients. In the end, these tools will help not only to facilitate the communication between doctors and patients and guide them to make decisions about the patient’s treatment together but will help researchers to detect new knowledge out of shared and joined health data combined with open access data.

Prof. Norbert Graf, coordinator of p-medicine, states in an interview: "The p-medicine project is facing the situation that even large diseases like breast cancer are divided into different subtypes. And each of these subtypes needs different treatment. To get these treatments to the correct patient, we need tools that are developed in p-medicine."

In the meeting's "public session", where the results of the project were presented to around 55 participants, emphasis was on the topics of patient empowerment and the progress made with regard to addressing legal and ethical requirements related to an infrastructure in which large sets of data are shared among numerous parties. Big data issues in general were also addressed by two key note speakers from Japan and the US. The public session closed with an outlook on STaRC, the Study Trial and Research Center to be found by a core team of p-medicine under the lead of Prof. Norbert Graf.

The second part of the meeting was a closed session dedicated to the evaluation of the project by the EC. The meeting ended with a very positive assessment by the EC officer and the reviewers regarding the technical implementation of the project. They particularly stressed the excellent leadership of this 19-partner project by p-medicine’s coordinator Prof. Norbert Graf.

The EU FP7 project p-medicine was one of a number of research projects arising from the broader VPH (Virtual Physiological Human) community. Research in p-medicine was devoted to creating an infrastructure that would facilitate the translation from current practice to personalised and preventive medicine. The emphasis was on formulating an open, modular framework of tools and services, so that p-medicine can be adopted gradually, including efficient secure sharing and handling of large personalized data sets and building standards-compliant tools and models. Privacy, non-discrimination, and access policies were aligned to maximize protection of and benefit to patients.

For further information, please visit:
http://www.p-medicine.eu

About p-medicine project
'p-medicine - From data sharing and integration via VPH models to personalized medicine' is a 4-year Integrated Project co-funded under the European Community's 7th Framework Programme aiming at developing new tools, IT infrastructure and VPH models to accelerate personalized medicine for the benefit of the patient.

In p-medicine 19 partners from 9 European countries and Japan have dedicated themselves to create support and sustain new knowledge and innovative technologies to overcome current problems in clinical research and pave the way for a more individualized therapy.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...